Results 11 to 20 of about 3,182,211 (266)

Artemisinin analogues as potent inhibitors of in vitro hepatitis C virus replication. [PDF]

PLoS ONE, 2013
We reported previously that Artemisinin (ART), a widely used anti-malarial drug, is an inhibitor of in vitro HCV subgenomic replicon replication. We here demonstrate that ART exerts its antiviral activity also in hepatoma cells infected with full length ...
Susan Obeid, Jo Alen, Van Hung Nguyen, Van Cuong Pham, Philip Meuleman, Christophe Pannecouque, Thanh Nguyen Le, Johan Neyts, Wim Dehaen, Jan Paeshuyse   +9 more
doaj   +27 more sources

High Prevalence of Anti-HCV Antibodies in Two Metropolitan Emergency Departments in Germany: A Prospective Screening Analysis of 28,809 Patients [PDF]

PLoS ONE, 2012
Background and Aims The prevalence of hepatitis C virus (HCV) antibodies in Germany has been estimated to be in the range of 0.4–0.63%. Screening for HCV is recommended in patients with elevated ALT levels or significant risk factors for HCV transmission
J. Vermehren, B. Schlosser, D. Domke, S. Elanjimattom, C. Müller, G. Hintereder, Karin Hensel-Wiegel, R. Tauber, A. Berger, N. Haas, F. Walcher, M. Möckel, R. Lehmann, S. Zeuzem, C. Sarrazin, T. Berg   +15 more
semanticscholar   +3 more sources

New preclinical antimalarial drugs potently inhibit hepatitis C virus genotype 1b RNA replication. [PDF]

PLoS ONE, 2013
BACKGROUND: Persistent hepatitis C virus (HCV) infection causes chronic liver diseases and is a global health problem. Although new triple therapy (pegylated-interferon, ribavirin, and telaprevir/boceprevir) has recently been started and is expected to ...
Youki Ueda, Midori Takeda, Kyoko Mori, Hiromichi Dansako, Takaji Wakita, Hye-Sook Kim, Akira Sato, Yusuke Wataya, Masanori Ikeda, Nobuyuki Kato   +9 more
doaj   +5 more sources

Evaluation of biochemical, hematological, RIBA and PCR assays in predicting viremia in anti-HCV positive patients

Journal of Infection in Developing Countries, 2019
Introduction: The detection of HCV-RNA by PCR assays is considered to be the gold standard for confirming the presence of HCV viremia. However, high costs, long and laborious procedures limit their widespread usage.
Mumtaz Cem Sirin, Buket Cicioglu Aridogan, Emel Sesli Cetin, Fevziye Burcu Sirin   +3 more
doaj   +3 more sources

Anti-HCV [PDF]

Springer Reference Medizin, 2019
openaire   +2 more sources

The diagnostic significance of hepatitis C virus antibody levels for chronic hepatitis C virus infection [PDF]

The Korean Journal of Internal Medicine, 2023
Background/Aims Although anti-hepatitis C virus (HCV) assay is widely used to screen for HCV infection, it has a high false-positive (FP) rate in low-risk populations.
Jin Gu Kang, Myoung Kuk Jang, Jung Hee Kim, Jang Han Jung, Ji Won Park, Sung Eun Kim, Sang Hoon Park, Myung Seok Lee, Ki Tae Suk, Dong Joon Kim, Hyoung Su Kim   +10 more
doaj   +1 more source

Structural basis for the inhibition of the SARS-CoV-2 main protease by the anti-HCV drug narlaprevir. [PDF]

Signal Transduct Target Ther, 2021
Bai Y, Ye F, Feng Y, Liao H, Song H, Qi J, Gao GF, Tan W, Fu L, Shi Y.   +9 more
europepmc   +3 more sources

Feasibility of anti-HCV reflex HCV Ag screening strategy in an HCV endemic community

Journal of the Formosan Medical Association, 2021
Background/Purpose: The HCV core antigen (HCV Ag) assay displays high sensitivity and strong correlation with HCV RNA. However, the feasibility of anti-HCV reflex HCV Ag screening in a community-wide setting is rarely discussed.
Wei-Ming Chen, Chih-Yi Lee, Nien-Tzu Hsu, Wei-Cheng Huang, Mei-Yen Chen, Tung-Jung Huang, Sheng-Nan Lu   +6 more
doaj   +1 more source

Prevalence and characteristics of hepatitis C virus infection in Shenyang City, Northeast China, and prediction of HCV RNA positivity according to serum anti-HCV level: retrospective review of hospital data

Virology Journal, 2020
Objective The prevalence of hepatitis C virus (HCV) infection is typically evaluated based on the current rate of positivity of anti-HCV antibody; however, HCV RNA positivity is considered the main criterion for antiviral treatment of HCV infection in ...
Yurong Li, Lianrong Zhao, Nan Geng, Weijia Zhu, Hongbo Liu, Han Bai   +5 more
doaj   +1 more source

Assessing the potential cost-effectiveness of centralised versus point-of-care testing for hepatitis C virus in Pakistan: a model-based comparison

BMJ Open, 2023
Objectives Pakistan has a hepatitis C virus (HCV) infection prevalence of 6%–9% and aims to achieve World Health Organisation (WHO) targets for elimination of HCV by the year 2030.
Louis P Garrison, Joseph B Babigumira, Samantha Clark, Saeed S Hamid, James K Karichu, Mindy M Cheng, Maciej B Maniecki   +6 more
doaj   +1 more source